Cargando…
Prevalence, treatment, and attributed mortality of elevated blood pressure among a nationwide population-based cohort of stroke survivors in China
BACKGROUND: Elevated blood pressure (BP) is associated with substantial morbidity and mortality in stroke survivors. China has the highest prevalence of stroke survivors and accounts for one-third of stroke-related deaths worldwide. We aimed to describe the prevalence and treatment of elevated BP ac...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561361/ https://www.ncbi.nlm.nih.gov/pubmed/36247443 http://dx.doi.org/10.3389/fcvm.2022.890080 |
_version_ | 1784807936491520000 |
---|---|
author | Wang, Bin Bai, Xueke Yang, Yang Cui, Jianlan Song, Lijuan Liu, Jiamin Lu, Jiapeng Cai, Jun |
author_facet | Wang, Bin Bai, Xueke Yang, Yang Cui, Jianlan Song, Lijuan Liu, Jiamin Lu, Jiapeng Cai, Jun |
author_sort | Wang, Bin |
collection | PubMed |
description | BACKGROUND: Elevated blood pressure (BP) is associated with substantial morbidity and mortality in stroke survivors. China has the highest prevalence of stroke survivors and accounts for one-third of stroke-related deaths worldwide. We aimed to describe the prevalence and treatment of elevated BP across age, sex, and region, and assess the mortality attributable to elevated BP among stroke survivors in China. MATERIALS AND METHODS: Based on 3,820,651 participants aged 35–75 years from all 31 provinces in mainland China recruited from September 2014 to September 2020, we assessed the prevalence and treatment of elevated BP (systolic BP ≥ 140 mmHg or diastolic BP ≥ 90 mmHg) among those with self-reported stroke and stratified by age group, sex, and geographic region. We estimated the age- and sex-specific population attributable fractions of death from elevated BP. RESULTS: Among 91,406 stroke survivors, the mean (SD) age was 62 (8) years, and 49.0% were male. The median interquartile range (IQR) stroke duration was 4 (2, 7) years. The prevalence of elevated BP was 61.3% overall, and increased with age (from 47.5% aged 35–44 years to 64.6% aged 65–75 years). The increment of prevalence was larger in female patients than male patients. Elevated BP was more prevalent in northeast (66.8%) and less in south (54.3%) China. Treatment rate among patients with elevated BP was 38.1%, and rates were low across all age groups, sexes, and regions. Elevated BP accounted for 33 and 21% of cardiovascular and all-cause mortality among stroke survivors, respectively. The proportion exceeded 50% for cardiovascular mortality among patients aged 35–54 years. CONCLUSION: In this nationwide cohort of stroke survivors from China, elevated BP and its non-treatment were highly prevalent across all age groups, sexes, and regions. Elevated BP accounted for nearly one-third cardiovascular mortality in stroke survivors, and particularly higher in young and middle-aged patients. National strategies targeting elevated BP are warranted to address the high stroke burden in China. |
format | Online Article Text |
id | pubmed-9561361 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95613612022-10-15 Prevalence, treatment, and attributed mortality of elevated blood pressure among a nationwide population-based cohort of stroke survivors in China Wang, Bin Bai, Xueke Yang, Yang Cui, Jianlan Song, Lijuan Liu, Jiamin Lu, Jiapeng Cai, Jun Front Cardiovasc Med Cardiovascular Medicine BACKGROUND: Elevated blood pressure (BP) is associated with substantial morbidity and mortality in stroke survivors. China has the highest prevalence of stroke survivors and accounts for one-third of stroke-related deaths worldwide. We aimed to describe the prevalence and treatment of elevated BP across age, sex, and region, and assess the mortality attributable to elevated BP among stroke survivors in China. MATERIALS AND METHODS: Based on 3,820,651 participants aged 35–75 years from all 31 provinces in mainland China recruited from September 2014 to September 2020, we assessed the prevalence and treatment of elevated BP (systolic BP ≥ 140 mmHg or diastolic BP ≥ 90 mmHg) among those with self-reported stroke and stratified by age group, sex, and geographic region. We estimated the age- and sex-specific population attributable fractions of death from elevated BP. RESULTS: Among 91,406 stroke survivors, the mean (SD) age was 62 (8) years, and 49.0% were male. The median interquartile range (IQR) stroke duration was 4 (2, 7) years. The prevalence of elevated BP was 61.3% overall, and increased with age (from 47.5% aged 35–44 years to 64.6% aged 65–75 years). The increment of prevalence was larger in female patients than male patients. Elevated BP was more prevalent in northeast (66.8%) and less in south (54.3%) China. Treatment rate among patients with elevated BP was 38.1%, and rates were low across all age groups, sexes, and regions. Elevated BP accounted for 33 and 21% of cardiovascular and all-cause mortality among stroke survivors, respectively. The proportion exceeded 50% for cardiovascular mortality among patients aged 35–54 years. CONCLUSION: In this nationwide cohort of stroke survivors from China, elevated BP and its non-treatment were highly prevalent across all age groups, sexes, and regions. Elevated BP accounted for nearly one-third cardiovascular mortality in stroke survivors, and particularly higher in young and middle-aged patients. National strategies targeting elevated BP are warranted to address the high stroke burden in China. Frontiers Media S.A. 2022-09-30 /pmc/articles/PMC9561361/ /pubmed/36247443 http://dx.doi.org/10.3389/fcvm.2022.890080 Text en Copyright © 2022 Wang, Bai, Yang, Cui, Song, Liu, Lu and Cai. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cardiovascular Medicine Wang, Bin Bai, Xueke Yang, Yang Cui, Jianlan Song, Lijuan Liu, Jiamin Lu, Jiapeng Cai, Jun Prevalence, treatment, and attributed mortality of elevated blood pressure among a nationwide population-based cohort of stroke survivors in China |
title | Prevalence, treatment, and attributed mortality of elevated blood pressure among a nationwide population-based cohort of stroke survivors in China |
title_full | Prevalence, treatment, and attributed mortality of elevated blood pressure among a nationwide population-based cohort of stroke survivors in China |
title_fullStr | Prevalence, treatment, and attributed mortality of elevated blood pressure among a nationwide population-based cohort of stroke survivors in China |
title_full_unstemmed | Prevalence, treatment, and attributed mortality of elevated blood pressure among a nationwide population-based cohort of stroke survivors in China |
title_short | Prevalence, treatment, and attributed mortality of elevated blood pressure among a nationwide population-based cohort of stroke survivors in China |
title_sort | prevalence, treatment, and attributed mortality of elevated blood pressure among a nationwide population-based cohort of stroke survivors in china |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561361/ https://www.ncbi.nlm.nih.gov/pubmed/36247443 http://dx.doi.org/10.3389/fcvm.2022.890080 |
work_keys_str_mv | AT wangbin prevalencetreatmentandattributedmortalityofelevatedbloodpressureamonganationwidepopulationbasedcohortofstrokesurvivorsinchina AT baixueke prevalencetreatmentandattributedmortalityofelevatedbloodpressureamonganationwidepopulationbasedcohortofstrokesurvivorsinchina AT yangyang prevalencetreatmentandattributedmortalityofelevatedbloodpressureamonganationwidepopulationbasedcohortofstrokesurvivorsinchina AT cuijianlan prevalencetreatmentandattributedmortalityofelevatedbloodpressureamonganationwidepopulationbasedcohortofstrokesurvivorsinchina AT songlijuan prevalencetreatmentandattributedmortalityofelevatedbloodpressureamonganationwidepopulationbasedcohortofstrokesurvivorsinchina AT liujiamin prevalencetreatmentandattributedmortalityofelevatedbloodpressureamonganationwidepopulationbasedcohortofstrokesurvivorsinchina AT lujiapeng prevalencetreatmentandattributedmortalityofelevatedbloodpressureamonganationwidepopulationbasedcohortofstrokesurvivorsinchina AT caijun prevalencetreatmentandattributedmortalityofelevatedbloodpressureamonganationwidepopulationbasedcohortofstrokesurvivorsinchina |